Teva Pharmaceuticals has successfully completed its $6.2bn acquisition of Cephalon following approval from European regulators.

What’s missing from your IPO industry assessment?
- Macroeconomic and demographic environment
- Consumer context
- Industry environment
- Competitive environment
- Route to market
Following the European Commission approval, Teva will divest marketing rights in France for a generic version of Cephalon narcolepsy medication Provigil.
The move comes after US authorities requested that Teva allow Par Pharmaceuticals to market a separate generic copy of Provigil for a year.
The acquisition has been designed to allow Teva to offset revenue losses associated with the patent expiry of multiple sclerosis drug Copaxone, the company’s biggest selling product.

What’s missing from your IPO industry assessment?
- Macroeconomic and demographic environment
- Consumer context
- Industry environment
- Competitive environment
- Route to market